Quest diagnostics launches novel prostate cancer test aimed at improving diagnosis and grading

Lab service utilizes envision science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer secaucus, n.j. and melbourne, australia , july 13, 2023 /prnewswire/ -- quest diagnostics (nyse: dgx), the leading provider of diagnostic information services, today announced the launch of a novel prostate cancer biomarker test through its subspecialty pathology business, ameripath, in collaboration with  envision sciences.
DGX Ratings Summary
DGX Quant Ranking